Evidence map›Paper›PMID 38182623›Full record

ArticleScientific reports2024

Synthesis and preclinical evaluation of a

Toni A Pringle, Erik Ramon-Gil, Jack Leslie, Fiona Oakley, Matthew C Wright, James C Knight, Saimir Luli

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Toni A PringleSchool of Natural and Environmental Sciences, Newcastle University, Bedson Building, Newcastle upon Tyne, NE1 7RU, UK.
Erik Ramon-GilNewcastle Fibrosis Research Group, Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Jack LeslieNewcastle Fibrosis Research Group, Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Fiona OakleyNewcastle Fibrosis Research Group, Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Matthew C WrightLiver Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
James C KnightSchool of Natural and Environmental Sciences, Newcastle University, Bedson Building, Newcastle upon Tyne, NE1 7RU, UK. james.knight2@newcastle.ac.uk.
Saimir LuliNewcastle Fibrosis Research Group, Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK. Saimir.luli@ncl.ac.uk.
Newcastle University · GB

Funding

Medical Research Council MR/K001949/1Medical Research Council MR/K0019494/1Medical Research Council MR/R023026/1Wellcome Trust
6 · The paper itself

Abstract

Synaptophysin is expressed on fibrogenic hepatic myofibroblasts. C1-3 is a single chain human antibody (scAb) that binds specifically to synaptophysin on hepatic myofibroblasts, providing a targeting vector for novel in vivo imaging agents of chronic liver disease. C1-3 and a negative control scAb, CSBD9, were radiolabelled with zirconium-89 via desferrioxamine chelation to enable non-invasive molecular imaging with positron emission tomography (PET). DFO-scAb conjugates were characterised by gel electrophoresis (SDS-PAGE) and MALDI-TOF spectrometry, and

Indexed as

MyofibroblastsTomography, X-Ray ComputedAnimalsHumansImmunoglobulinsLiverMiceSynaptophysinImmunoglobulinsSynaptophysin

Identifiers

PMID38182623
PMCPMC10770171
OpenAlexW4390616997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.